Compare Tango Therapeutics Inc. (TNGX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 13.9× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard Short Term Corporate Bond ETF for 54 Days on average.
| TNGX | VCSH | |
|---|---|---|
Market Cap | $3.74B | $51.90B |
Volume | 3,438,781 | 12,465,005 |
Sector | Health | Fixed Income |
52-Week High | $32.90 | $80.20 |
52-Week Low | $7.50 | $77.03 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VCSH trades at $77.32, down 0.05% with a bearish technical signal. The ETF offers a competitive yield around 4.5% with a short 2.7-year duration, providing stability amid rising rates. Recent news highlights VCSH's lower expense ratio of 0.03% compared to peers and its focus on investment-grade corporate bonds. However, technical indicators show selling pressure with RSI at overbought levels and bearish moving average signals.
The outlook remains cautious due to tight credit spreads and limited price appreciation potential. While VCSH provides higher yield than treasury alternatives, it carries greater credit risk. Recent institutional activity shows mixed sentiment with both position increases and decreases reported. The ETF's short duration minimizes interest rate risk but faces headwinds from compressed spreads and competitive pressure from broader bond ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
